Your browser doesn't support javascript.
loading
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
Sutera, Philip; Deek, Matthew P; Van der Eecken, Kim; Shetty, Amol C; Chang, Jin Hee; Hodges, Theresa; Song, Yang; Verbeke, Sofie; Van Dorpe, Jo; Fonteyne, Valérie; De Laere, Bram; Mishra, Mark; Rana, Zaker; Molitoris, Jason; Ferris, Matthew; Ross, Ashley; Schaeffer, Edward; Roberts, Nicholas; Song, Daniel Y; DeWeese, Theodore; Pienta, Kenneth J; Antonarakis, Emmanuel S; Ost, Piet; Tran, Phuoc T.
Afiliación
  • Sutera P; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Deek MP; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.
  • Van der Eecken K; Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Pathology, Ghent University Hospital, Ghent, Belgium.
  • Shetty AC; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Chang JH; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Hodges T; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Song Y; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Verbeke S; Department of Pathology, Ghent University Hospital, Ghent, Belgium.
  • Van Dorpe J; Department of Pathology, Ghent University Hospital, Ghent, Belgium.
  • Fonteyne V; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
  • De Laere B; Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Medical Epidemiology, Biostatistics Karolinska Institute, Stockholm, Sweden.
  • Mishra M; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Rana Z; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Molitoris J; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Ferris M; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Ross A; Department of Urology, Northwestern University, Chicago, Illinois.
  • Schaeffer E; Department of Urology, Northwestern University, Chicago, Illinois.
  • Roberts N; Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Song DY; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; James Buchanan Brady Urologic Inst
  • DeWeese T; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; James Buchanan Brady Urologic Inst
  • Pienta KJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; James Buchanan Brady Urologic Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Antonarakis ES; Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota.
  • Ost P; Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Iridium Network, Antwerp, Belgium. Electronic address: piet.ost@ugent.be.
  • Tran PT; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: phuoc.tran@som.umaryland.edu.
Int J Radiat Oncol Biol Phys ; 115(5): 1095-1101, 2023 04 01.
Article en En | MEDLINE | ID: mdl-36708787
ABSTRACT

PURPOSE:

WNT signaling is a cellular pathway that has been implicated in the development and progression of prostate cancer. Oligometastatic castration-sensitive prostate cancer (omCSPC) represents a unique state of disease in which metastasis-directed therapy (MDT) has demonstrated improvement in progression-free survival. Herein, we investigate the clinical implications of genomic alterations in the WNT signaling cascade in men with omCSPC. METHODS AND MATERIALS We performed an international multi-institutional retrospective study of 277 men with metachronous omCSPC who underwent targeted DNA sequencing of their primary/metastatic tumor. Patients were classified by presence or absence of pathogenic WNT pathway mutations (in the genes APC, RNF43, and CTNNB1). Pearson χ2 and Mann-Whitney U tests were used to determine differences in clinical factors between genomic strata. Kaplan-Meier survival curves were generated for radiographic progression-free survival and overall survival, stratified according to WNT pathway mutation status.

RESULTS:

A pathogenic WNT pathway mutation was detected in 11.2% of patients. Patients with WNT pathway mutations were more likely to have visceral metastases (22.6% vs 2.8%; P < .01) and less likely to have regional lymph node metastases (29.0% vs 50.4%; P = .02). At time of oligometastasis, these patients were treated with MDT alone (33.9%), MDT + limited course of systemic therapy (20.6%), systemic therapy alone (22.4%), or observation (defined as no treatment for ≥6 months after metastatic diagnosis). Multivariable cox regression demonstrated WNT pathway mutations associated with significantly worse overall survival (hazard ratio, 3.87; 95% confidence interval, 1.25-12.00).

CONCLUSIONS:

Somatic WNT pathway alterations are present in approximately 11% of patients with omCSPC and are associated with an increased likelihood of visceral metastases. Although these patients have a worse natural history, they may benefit from MDT.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Vía de Señalización Wnt Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Vía de Señalización Wnt Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2023 Tipo del documento: Article